Biogen Idec Accelerates Development Of Rheumatoid Arthritis Candidate On Phase IIa Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Company has initiated trials of the lymphotoxin beta fusion protein in two key RA patient populations.
You may also be interested in...
Biogen First-In-Class Baminercept Shows Benefits For RA Patients In Phase IIa
Dual mechanism lymphotoxin-ß/LIGHT pathway inhibitor demonstrates a 60 percent improvement in swollen joints after 35 days.
Biogen First-In-Class Baminercept Shows Benefits For RA Patients In Phase IIa
Dual mechanism lymphotoxin-ß/LIGHT pathway inhibitor demonstrates a 60 percent improvement in swollen joints after 35 days.
Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s
Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.